Quest Diagnostics announced that it has acquired PhenoPath, a national provider of specialized anatomic pathology and related services. Based in Seattle, PhenoPath provides AP, molecular oncology and other services that complement and extend those of the company’s Advanced Diagnostics portfolio of services. These include services, such as genetic sequencing and genomic tumor analysis, which require higher-order expertise and skill. The PhenoPath business will operate as part of AmeriPath, a wholly owned business of Quest Diagnostics. The leading provider of anatomic pathology services, AmeriPath provides high-end pathology services to many ambulatory health and surgery centers, imaging centers, clinics and physician offices, and has on-site community pathologists in more than 170 hospitals across the country. Additional terms of the transaction were not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.